• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Effect of Catheter Ablation vs Antiarrhythmic Drugs on Mortality, Stroke, Bleeding, and Cardiac Arrest in AF
This randomized trial compares the effect of pulmonary vein isolation via catheter ablation vs rate and rhythm control using medical therapy on a composite outcome of death, disabling stroke, serious bleeding, or cardiac arrest in patients with atrial fibrillation (AF).
Source: JAMA - Journal of the American Medical Association - March 15, 2019 Category: General Medicine Source Type: research

Warfarin Use May Not Bring Long-Term Stability for Atrial Fibrillation
Contact: Amara Omeokwe Phone: 919-681-4239 Email:amara.omeokwe@duke.eduhttps://www.dukehealth.orgEMBARGOED FOR RELEASE until 11 a.m. (ET) on Tuesday, Aug. 9, 2016DURHAM, N.C. -- Warfarin prescribed to prevent strokes in atrial fibrillation may not adequately control blood clotting over the long-term, even when patients have been historically stable on the drug, according to a study from the Duke Clinical Research Institute.The findings, published Aug. 9 in the Journal of the American Medical Association (JAMA), are based on an 18-month study of 3,749 patients diagnosed with atrial fibrillation, an irregular heart rhythm. T...
Source: DukeHealth.org: Duke Health Features - August 9, 2016 Category: Pediatrics Tags: Duke Medicine Source Type: news

Bivalirudin vs Heparin With or Without Tirofiban During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction The BRIGHT Randomized Clinical Trial
ImportanceThe safety and efficacy of bivalirudin compared with heparin with or without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI) are uncertain.ObjectiveTo determine if bivalirudin is superior to heparin alone and to heparin plus tirofiban during primary PCI.Design, Setting, and ParticipantsMulticenter, open-label trial involving 2194 patients with AMI undergoing primary PCI at 82 centers in China between August 2012 and June 2013.InterventionsPatients were randomly assigned to receive bivalirudin with a post-PCI infusion (...
Source: JAMA - Journal of the American Medical Association - March 16, 2015 Category: Journals (General) Source Type: research

Stroke treatment, outcomes improve at hospitals participating in UCLA-led initiative
Administering a clot-dissolving drug to stroke victims quickly — ideally within the first 60 minutes after they arrive at a hospital emergency room — is crucial to saving their lives, preserving their brain function and reducing disability. Given intravenously, tPA (tissue plasminogen activator) is currently the only Food and Drug Administration–approved therapy shown to improve outcomes for patients suffering acute ischemic stroke, which affects some 800,000 Americans annually. Now, a UCLA-led study demonstrates that hospitals participating in the "Target: Stroke" national quality-improvement program have markedly...
Source: UCLA Newsroom: Health Sciences - April 23, 2014 Category: Universities & Medical Training Source Type: news

Timely treatment after stroke is crucial, UCLA researchers report
For years, the mantra of neurologists treating stroke victims has been "time equals brain." That's because getting a patient to the emergency room quickly to receive a drug that dissolves the stroke-causing blood clot can make a significant difference in how much brain tissue is saved or lost.   But specific information has been limited on just how the timing of giving the intravenous drug — known as a tissue plasminogen activator, or tPA — influences outcomes for victims of ischemic (clot-caused), stroke, the most common type of stroke.   Now, a team led by UCLA researchers has conducted a major stud...
Source: UCLA Newsroom: Health Sciences - June 18, 2013 Category: Universities & Medical Training Source Type: news